Bioblast Pharma Ltd.
- Country
- 🇮🇱Israel
- Ownership
- Public, Subsidiary
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://bioblast-pharma.com
Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Bioblast Pharma Ltd.
- Registration Number
- NCT04226924
- Locations
- 🇨🇦
Ecogene-21, Chicoutimi, Quebec, Canada
🇨🇦Montreal Neurological Institute and Hospital, Montréal, Quebec, Canada
🇨🇦CHU de Québec-Université Laval- Hôpital Enfant-Jésus, Québec, Quebec, Canada
A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects
- Conditions
- Healthy Volunteer Subjects
- Interventions
- Drug: Saline 0.9% IV
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Bioblast Pharma Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02725957
- Locations
- 🇺🇸
PAREXEL Baltimore Early Phase Clinical Unit; Harbor Hospital, Baltimore, Maryland, United States
Continuation Protocol to Protocol BBCO-001
- Conditions
- Muscular Dystrophy, Oculopharyngeal (OPMD)
- Interventions
- Drug: Tehalose 30gr
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Bioblast Pharma Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT02328482
- Locations
- 🇨🇦
Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease
- Conditions
- Machado-Joseph Disease / Spinocerebellar Ataxia 3
- Interventions
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Bioblast Pharma Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT02147886
- Locations
- 🇮🇱
Meir Medical Center, Kfar Saba, Israel
Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- Bioblast Pharma Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02015481
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Tahseen Mozaffar, Orange, California, United States
🇨🇦Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada